PROFOUND MEDICAL CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12 CAD | -2.60% |
|
-3.38% | +8.11% |
| 05-15 | Transcript : Profound Medical Corp. - Shareholder/Analyst Call | |
| 05-14 | Sector Update: Health Care Stocks Steady Premarket Tuesday | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 174.8 | 514 | 296.2 | 302.3 | 266.8 | 293.8 | - | - |
| Enterprise Value (EV) 1 | 174.8 | 514 | 296.2 | 302.3 | 242.2 | 293.8 | 293.8 | 293.8 |
| P/E ratio | -8.1 x | -16.6 x | -7.5 x | -7.64 x | -6.11 x | -7.52 x | -9.17 x | -11.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 31.6 x | 55.8 x | 34 x | 32.9 x | 27.5 x | 19 x | 6.99 x | 4.33 x |
| EV / Revenue | 31.6 x | 55.8 x | 34 x | 32.9 x | 27.5 x | 19 x | 6.99 x | 4.33 x |
| EV / EBITDA | -9.85 x | -23.5 x | -11 x | -9.26 x | -8.24 x | -7.85 x | -10.9 x | -18.3 x |
| EV / FCF | -8,728,118 x | -19,797,746 x | -10,431,961 x | -8,528,573 x | -8,885,188 x | - | - | - |
| FCF Yield | -0% | -0% | -0% | -0% | -0% | - | - | - |
| Price to Book | 9.37 x | 3.69 x | - | 4.21 x | 5.65 x | 8.53 x | 97.6 x | -17.9 x |
| Nbr of stocks (in thousands) | 11,853 | 19,626 | 20,769 | 20,876 | 24,033 | 24,481 | - | - |
| Reference price 2 | 14.75 | 26.19 | 14.26 | 14.48 | 11.10 | 12.00 | 12.00 | 12.00 |
| Announcement Date | 03/03/20 | 02/03/21 | 03/03/22 | 07/03/23 | 07/03/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.528 | 9.217 | 8.714 | 9.178 | 9.694 | 15.49 | 42 | 67.88 |
| EBITDA 1 | -17.75 | -21.86 | -26.89 | -32.64 | -32.39 | -37.44 | -26.99 | -16.09 |
| EBIT 1 | -19.77 | -23.8 | -38.41 | -40.67 | -38.53 | -40.44 | -34.62 | -33.24 |
| Operating Margin | -357.63% | -258.26% | -440.72% | -443.08% | -397.5% | -261.06% | -82.42% | -48.97% |
| Earnings before Tax (EBT) 1 | -20 | -27.23 | -38.79 | -38.99 | -38.64 | -40.11 | -34.86 | -33.24 |
| Net income 1 | -20.19 | -27.29 | -38.92 | -39.39 | -38.47 | -40.35 | -29.45 | -31.23 |
| Net margin | -365.3% | -296.03% | -446.66% | -429.11% | -396.85% | -260.5% | -70.12% | -46% |
| EPS 2 | -1.820 | -1.577 | -1.902 | -1.896 | -1.818 | -1.596 | -1.309 | -1.048 |
| Free Cash Flow | -20.03 | -25.96 | -28.39 | -35.44 | -30.02 | - | - | - |
| FCF margin | -362.37% | -281.68% | -325.8% | -386.17% | -309.72% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 03/03/20 | 02/03/21 | 03/03/22 | 07/03/23 | 07/03/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.265 | 1.772 | 2.603 | 2.796 | 1.727 | 2.486 | 2.154 | 2.383 | 2.705 | 2.614 | 3.343 | 4.185 | 5.356 | 12.38 | 15.13 |
| EBITDA 1 | -8.646 | -7.79 | -7.315 | -9.142 | -9.376 | -7.504 | -7.15 | -7.649 | -10.2 | -8.772 | -7.999 | -9.094 | -11.96 | - | - |
| EBIT 1 | -12.33 | -9.471 | -9.999 | -11.31 | -8.652 | -9.14 | -8.655 | -9.047 | -11.83 | -10.24 | -8.902 | -9.484 | -11.12 | - | - |
| Operating Margin | -974.75% | -534.6% | -384.1% | -404.62% | -501.04% | -367.63% | -401.75% | -379.63% | -437.13% | -391.73% | -266.27% | -226.62% | -207.56% | - | - |
| Earnings before Tax (EBT) 1 | -12.92 | -10.63 | -7.603 | -6.818 | -12.81 | -8.947 | -9.843 | -7.649 | -12.3 | -8.43 | -8.409 | -9.503 | -12.24 | - | - |
| Net income 1 | -12.88 | -10.67 | -7.623 | -6.864 | -13.09 | -9.074 | -9.89 | -7.673 | -12 | -8.483 | -9.014 | -9.589 | -11.26 | - | - |
| Net margin | -1,018.14% | -602.27% | -292.84% | -245.55% | -757.92% | -364.95% | -459.11% | -321.99% | -443.45% | -324.56% | -269.61% | -229.13% | -210.26% | - | - |
| EPS 2 | -0.6213 | -0.5195 | -0.3600 | -0.3297 | -0.6319 | -0.4277 | -0.4706 | -0.3586 | -0.5655 | -0.3558 | -0.3898 | -0.3998 | -0.4238 | -0.3690 | -0.3280 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 03/03/22 | 09/05/22 | 04/08/22 | 03/11/22 | 07/03/23 | 10/05/23 | 09/08/23 | 02/11/23 | 07/03/24 | 09/05/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | 24.6 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -20 | -26 | -28.4 | -35.4 | -30 | - | - | - |
| ROE (net income / shareholders' equity) | -89.2% | -38.7% | - | -43.2% | -68.7% | -116% | -1,010% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 1.570 | 7.100 | - | 3.440 | 1.960 | 1.410 | 0.1200 | -0.6700 |
| Cash Flow per Share 2 | -1.800 | -1.500 | - | -1.710 | -1.420 | -0.3800 | -1.240 | -0.5300 |
| Capex 1 | - | - | 0.04 | - | - | - | - | - |
| Capex / Sales | - | - | 0.47% | - | - | - | - | - |
| Announcement Date | 03/03/20 | 02/03/21 | 03/03/22 | 07/03/23 | 07/03/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
12
CAD
Average target price
12.5
CAD
Spread / Average Target
+4.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.11% | 214M | |
| +7.23% | 217B | |
| +11.31% | 191B | |
| +28.94% | 154B | |
| +32.00% | 112B | |
| +0.15% | 62.75B | |
| +16.09% | 53.34B | |
| +0.94% | 48.88B | |
| -2.97% | 39.36B | |
| +1.23% | 35.73B |
- Stock Market
- Equities
- PRN Stock
- Financials Profound Medical Corp.
